Abbott's new cancer agent has promising results in Phase 1 trial

Abbott Laboratories' cancer drug proved to be promising in its Phase I study after it showed signs of shrinking lung tumors, said a doctor who performed an earlier trial in Singapore.

The Phase II trial of the medicine, known as ABT-869, will begin by the end of the year in about 60 lung and 60 liver cancer patients, said Goh Boon Cher, an oncologist at Singapore's National University Hospit...